Skip to content

In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment at the Time of Coronary Angiography Affect Management Strategy, Hospital Costs and Outcomes?

A Randomised Controlled Trial to Compare Routine Pressure Wire Assessment With Conventional Angiography in the Management of Patients With Coronary Artery Disease.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02892903
Acronym
RIPCORD 2
Enrollment
1100
Registered
2016-09-08
Start date
2016-09-30
Completion date
2020-03-31
Last updated
2019-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome, Chest Pain, Non ST Segment Elevation Acute Coronary Syndrome, Stable Angina

Keywords

Fractional flow reserve (FFR), Pressure wire (PW), Coronary angiography

Brief summary

A randomised controlled trial to compare two strategies for the investigation of coronary artery disease at the time of angiography. Patients will be randomised to conventional angiography or additional, routine pressure wire assessment - measuring fractional flow reserve (FFR) - in all main vessels judged as being of sufficient vessel calibre to allow percutaneous coronary intervention (PCI) (experimental arm).

Detailed description

The study will recruit patients undergoing angiography for the investigation of stable angina or for the assessment of a recent, but stabilised, non-ST elevation acute coronary syndrome event. Eligible patients who provide written informed consent will be randomised to conventional angiography or additional, routine pressure wire assessment - measuring fractional flow reserve (FFR) - in all main vessels judged as being of sufficient vessel calibre to allow percutaneous coronary intervention (PCI) (experimental arm). The study pragmatic design allows investigators to conduct all diagnostic and therapeutic management in accordance with prevailing best practice patterns. Study outcome measures will examine resource utilisation, patient reported quality of life and clinical events at 1 year.

Interventions

DEVICERoutine Measurement of FFR

FFR measurement will be performed in all major vessels with normal (TIMI 3) flow. Occluded vessels and vessels with TIMI flow \<3 will not be examined but will be 'awarded' an FFR value of 0.5

Sponsors

Liverpool Heart and Chest Hospital NHS Foundation Trust
CollaboratorOTHER
University Hospital Southampton NHS Foundation Trust
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

· Inclusion criteria o Outline Initial Inclusion Criteria (before entry to cath lab): Patient scheduled for coronary angiography for the: * Elective investigation of known or suspected coronary artery disease OR * Urgent investigation of a recent but stabilised, non-ST elevation acute coronary syndrome event o Outline Angiographic Inclusion Criterion (after angiography): * Presence of significant coronary disease defined as: Any stenosis \>30% reduction in luminal diameter, by visual estimate, in at least one vessel (main or branch) of sufficient calibre to permit the potential performance of PCI - approximately 2.25 mm diameter. * Key

Exclusion criteria

* Screening phase

Design outcomes

Primary

MeasureTime frameDescription
Primary Economic Outcome MeasureOne yearResource utilisation as determined by hospital care costs at one year; All hospital admissions will be tracked using national hospital episode statistics; the cost of each episode will be derived from a cost model using standard UK tariffs. This analysis will compare the mean (or median) of the total hospital costs recorded for each patient over the 12 month follow-up period.
Primary Quality of Life Outcome MeasureOne yearPatient reported quality of life at one year using the EQ-5D health questionnaire.

Secondary

MeasureTime frameDescription
All-cause mortalityOne year
Number of hospitalisation eventsOne year
Management strategy informationReported once: Single declaration at index procedure after randomisation· Proportion of vessels deemed to demonstrate flow-limiting disease and targeted for revascularisation in the declared initial management strategy.
Hospitalisation eventsOne yearHospitalisation events coded as cerebro-vascular accident (CVA).
Total hospital daysOne year
Angina symptomsOne year• Angina symptoms as reported by the research team after the 12 month contact, described by Canadian Cardiovascular Society Grade.

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 24, 2026